top of page

KRAS Cancer News & Updates



Getting ahold of KRAS Science: Visiting Kevan Shokat at his UCSF Lab
By the time I met Kevan Shokat, KRAS G12D was already the name of the devil my body was fighting.
Then Kevan did something extraordinary. He made me a three dimensional model of KRAS, had it painted, and sent it to me with a handwritten letter.

Terri Conneran KRAS Kickers
Sep 28


How KRAS Became Druggable: Kevan Shokat and the Pocket That Opened a New Era of RAS Drugs
more than 60 additional drugs targeting the RAS family are now in development. What began with a chemical foothold in KRAS G12C has become an expanding field of RAS drug discovery. Why This Matters for People With KRAS Cancer The science also explains why knowing the exact KRAS variant matters.

Terri Conneran KRAS Kickers
Sep 28


Lung Cancer Patients Want to Know About Daraxonrasib: What Does RAS Mutant Mean?
By Terri Conneran, Founder, KRAS Kickers Reviewed for clinical accuracy by Salman R. Punekar, MD, MSc, Perlmutter Cancer Center at NYU Langone Health For this daraxonrasib lung cancer study, eligible RAS mutations were found at G12, G13, or Q61. The exact gene and exact mutation still matter because different RAS mutations can behave differently and may affect treatment or clinical trial options. For example, KRAS G12D, KRAS G12V, and KRAS G12C are all RAS mutations, but they


Val: A Life of Courage, Faith, and Hope
Val’s Advice to Others Facing Lung Cancer
...a quiet but powerful advocate, offering guidance to other people, especially young adults with cancer:
“Don’t freak out when you’re diagnosed. And don’t go straight to Google. Statistics don’t define you
KRAS Cancer Connect
Jul 29, 2025


Cancer Treatment & Clinical Trial Eligibility: What Patients Need to Know
Once you know your options, the next question is: Am I eligible? Here’s how doctors typically determine if a patient qualifies for a clinical trial or specific therapy—regardless of cancer type.
6 things that matter...

Terri Conneran KRAS Kickers
Jul 11, 2025


What Every Cancer Patient Should Know About Today’s Treatment Options
..just been diagnosed—or are navigating next step—you’re not alone. Cancer care has changed dramatically in the last decade. Today, you may have more treatment choices than ever before. This post is designed to help you understand your options and feel confident asking the right questions.

Terri Conneran KRAS Kickers
Jul 11, 2025


What Is ASCO Conference—And Should Cancer Patients Care?
💡 Why It Matters to Patients:
Even if you’re not in the room, what happens at ASCO can shape your treatment options—now and in the future. KRAS-driven cancers (lung, colon, pancreatic, and rare cancers) are a major area of focus at ASCO. knowing what’s coming can help you:
-Ask better questions -
-Stay ahead of the curve -
-Find hope in options you didn’t know existed- Gen-Me Medicine—where cancer care is about matching the right treatment to your unique molecular fingerpri

Terri Conneran KRAS Kickers
Jun 10, 2025


Precision Medicine has Empowered Cancer Patients
One of the patient voices from this documentary is Terri Conneran: Empowering the Patients For Precision Cancer Advocacy In the documentary, powerful stories from patients, industry experts, and healthcare providers about how precision medicine has empowered their healthcare decisions, providing renewed hope .

Terri Conneran KRAS Kickers
Jun 5, 2025


Essential Guide to Cancer Biomarkers For Cancer Patients
Need to know what mutation is driving the cancer bus. It's different than noise from the back of the bus.
Biomarkers testing tells us what to Aim for as the cancer driver, not the background noise. Taking out the cancer driver can make the difference.
Biomarkers provide the insights as to what is driving the cancer.

Terri Conneran KRAS Kickers
Apr 22, 2025


KICKING KRAS LUNG CANCER!
Upstage Lung Cancer heard the power of hope to kick cancer from Terri Conneran

Terri Conneran KRAS Kickers
Dec 19, 2024


Laurie S
I Thought! ‘ I must be really out of shape’ Laurie shares her hope from living with lung cancer

Terri Conneran KRAS Kickers
Apr 4, 2023
Roller Coaster Ride with lung cancer Kristi C.
Kristi shares with others about her KRAS lung cancer diagnosis and experience with clinical trials.

C Schlatt
Sep 16, 2022


Deborah C.
After listening to Deborah's story, it's clear that she has been through an incredible journey. She gives insight into what it was like...

C Schlatt
Jul 1, 2022


I told the doctor you're in the wrong room!
Brenda's journey resonates with hope . Her story started nine months ago. Brenda recalls her experiences leading up until the moment she...

C Schlatt
Jun 3, 2022
Rachelle's Journey
How I Get Through This People often ask me, “What gets you through all of this?” In other words, how do I manage as a lung cancer...

C Schlatt
Apr 22, 2022


Allison ... in her own words
I was diagnosed with non-small cell lung cancer (NSCLC) on April 6, 2018. I had actually started feeling bad in January of 2018, on my...

Terri Conneran KRAS Kickers
Nov 30, 2021


Terri's Journey to KRAS Kickers
Terri shares her stage 3A KRAS+ lung cancer story, including experiencing three separate recurrences. She persevered through multiple...

ThePatientStory
Apr 16, 2021


James H.
763: That is how many consecutive days I had been running at least one mile—also known as a running streak. Surgery ended that. On what...

Terri Conneran KRAS Kickers
Apr 7, 2021
Getting ahold of KRAS Science: Visiting Kevan Shokat at his UCSF Lab
By the time I met Kevan Shokat, KRAS G12D was already the name of the devil my body was fighting.
Then Kevan did something extraordinary. He made me a three dimensional model of KRAS, had it painted, and sent it to me with a handwritten letter.
How KRAS Became Druggable: Kevan Shokat and the Pocket That Opened a New Era of RAS Drugs
more than 60 additional drugs targeting the RAS family are now in development. What began with a chemical foothold in KRAS G12C has become an expanding field of RAS drug discovery. Why This Matters for People With KRAS Cancer The science also explains why knowing the exact KRAS variant matters.
Where can patients find the NCCN guidelines used to guide cancer treatment?
NCCN Guidelines help clinicians determine what evaluations are appropriate, which treatment options are supported by current evidence, when additional testing may be important, and how care may change as a cancer changes.For patients, NCCN offers a version for patients.

bottom of page




